宜明昂科-b(01541)涨超10%,截至发稿,涨10.69%,报7.66港元,成交额4002.39万港元。消息面上,宜明昂科近日宣布,泰泽苏拜单抗(tazlestobart,IMM27M)联合奥希替尼针对EGFR突变的局部晚期或转移性非鳞非小细胞肺癌的Ib/II期临床试验申请,已正式获得国家药品监督管理局(NMPA)批准。另外,公司月初公布,就其2024年8月1日与Axion Bio,Inc.(...
Source Link宜明昂科-b(01541)涨超10%,截至发稿,涨10.69%,报7.66港元,成交额4002.39万港元。消息面上,宜明昂科近日宣布,泰泽苏拜单抗(tazlestobart,IMM27M)联合奥希替尼针对EGFR突变的局部晚期或转移性非鳞非小细胞肺癌的Ib/II期临床试验申请,已正式获得国家药品监督管理局(NMPA)批准。另外,公司月初公布,就其2024年8月1日与Axion Bio,Inc.(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.